Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 15;13(10):11522-11530.
eCollection 2021.

Bosentan combined with sildenafil in the treatment of COPD patients with pulmonary arterial hypertension

Ying Li  1 , Yao Wang  2 , Shaohua Liu  3
Affiliations

Bosentan combined with sildenafil in the treatment of COPD patients with pulmonary arterial hypertension

Ying Li et al. Am J Transl Res. .

Abstract

Objective: To explore the impacts of bosentan combined with sildenafil on chronic obstructive pulmonary disease (COPD) patients with pulmonary arterial hypertension (PAH).

Methods: From April 2019 to October 2020, 90 COPD patients with PAH diagnosed in our hospital were recruited and divided into groups A and B. The patients in group A (50 cases) were treated with bosentan combined with sildenafil, and the patients in group B (40 cases) were administered bosentan combined with iloprost solution for inhalation. The PAH conditions, the heart rates (HR), the cardiac function, the pulmonary function, the blood gas indexes, the inflammatory factor expressions, the incidences of adverse reactions, the overall response rates (ORR), and the patient satisfaction levels were determined or evaluated.

Results: Compared with group B, the patients in group A had better recovered PAH, HR, cardiac function, pulmonary function, and blood gas indexes, lower inflammatory factor expression levels and a lower incidence of adverse reactions, as well as higher ORR and higher satisfaction levels.

Conclusion: Bosentan combined with sildenafil can reduce pulmonary artery pressure and promote the recovery of cardiopulmonary function in COPD patients with PAH.

Keywords: Chronic obstructive pulmonary disease; bosentan; pulmonary arterial hypertension; sildenafil.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
The pulmonary artery pressures and the heart rates in the two groups of patients. A. Pulmonary artery pressure: both groups of patients have significantly changed pulmonary artery pressure, and it was lower in group A than in group B after the treatment (P<0.05). B. Heart rate: both groups of patients have significantly changed heart rates, and they were lower in group A than in group B after the treatment (P<0.05). Notes: *P<0.05 vs. on admission, #P<0.05 vs. group B.
Figure 2
Figure 2
Cardiac function of two groups of patients. A. 6MWD: both groups of patients have significantly changed 6MWD, which was higher in group A than in group B after the treatment (P<0.05). B. RVEF: both groups of patients have significantly changed RVEF, which was higher in group A than in group B after the treatment (P<0.05). Notes: *P<0.05 vs. on admission, #P<0.05 vs. group B.
Figure 3
Figure 3
The pulmonary function and blood gas indexes of two groups of patients. A. FEV1: both groups of patients have significantly changed FEV1, which was higher in group A than in group B after the treatment (P<0.05). B. FVC: both groups of patients have significantly changed FVC, which was higher in group A than in group B after the treatment (P<0.05). C. FEV1/FVC: both groups of patients have significantly changed FEV1/FVC, which was higher in group A than in group B after the treatment (P<0.05). D. PaO2: there were significant changes in both groups in PaO2, and PaO2 in group A was higher than that in group B after treatment (P<0.05). E. PaCO2: there were significant changes in both groups in PaCO2, and PaCO2 in group A was lower than that in group B after treatment (P<0.05). Notes: *P<0.05 vs. on admission, #P<0.05 vs. group B.
Figure 4
Figure 4
The inflammatory factor levels of the two groups of patients. A. IL-13: both groups of patients have significantly changed IL-13, which was lower in group A than in group B after treatment (P<0.05). B. IL-17: both groups of patients have significantly changed IL-17, which was lower in group A than in group B after treatment (P<0.05). C. CRP: both groups of patients have significantly changed CRP, which is lower in group A than in group B after treatment (P<0.05). Notes: *P<0.05 vs. on admission, #P<0.05 vs. group B.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Zhu B, Wang Y, Ming J, Chen W, Zhang L. Disease burden of COPD in China: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:1353–1364. - PMC - PubMed
    1. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet Respir Med. 2017;5:691–706. - PMC - PubMed
    1. Sood A, Assad NA, Barnes PJ, Churg A, Gordon SB, Harrod KS, Irshad H, Kurmi OP, Martin WJ 2nd, Meek P, Mortimer K, Noonan CW, Perez-Padilla R, Smith KR, Tesfaigzi Y, Ward T, Balmes J. ERS/ATS workshop report on respiratory health effects of household air pollution. Eur Respir J. 2018;51:1700698. - PMC - PubMed
    1. Barnes PJ. Oxidative stress-based therapeutics in COPD. Redox Biol. 2020;33:101544. - PMC - PubMed
    1. Wang Y, Xu J, Meng Y, Adcock IM, Yao X. Role of inflammatory cells in airway remodeling in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3341–3348. - PMC - PubMed

LinkOut - more resources